DLH to Present at the Canaccord Genuity Conference on August 7

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ATLANTA, July 22, 2019 /PRNewswire/ — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of innovative healthcare services and solutions to federal agencies, today announced that it will participate in the Canaccord Genuity 39th Annual Growth Conference on August 7, 2019 in Boston, where management will provide an overview of the Company’s operations and outlook. Institutional investors are welcome to participate in one-on-one meetings throughout the day, and a live audio webcast of the Company’s discussion will be available on the DLH website.

About DLH
DLH (NASDAQ:DLHC) serves federal government clients throughout the United States and abroad delivering technology enabled solutions in key health and human services programs. The Company’s core competencies and consulting services include assessment and compliance monitoring, program management, health IT systems integration, data analytics, medical logistics, and pharmacy solutions. DLH has over 1,600 employees serving numerous government agencies. For more information, visit the corporate website at www.dlhcorp.com

DLH Investor Relations
Contact: Chris Witty
Phone:  646-438-9385
Email:  cwitty@darrowir.com

 

View original content:http://www.prnewswire.com/news-releases/dlh-to-present-at-the-canaccord-genuity-conference-on-august-7-300887570.html

SOURCE DLH Holdings Corp.

Staff

Recent Posts

Introducing Tempus One in the EHR with Integrated Guidelines

The AI-enabled clinical assistant is available to query patient data across the EHR as well…

8 hours ago

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC)…

8 hours ago

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep,…

8 hours ago